Longevity Startups

Manna Tree Partners is an investment firm that backs consumer health and wellness companies, focusing on brands and products tied to longevity and healthier living. This is a VC/investment firm page rather than an operating portfolio company.

1 investor

Megakaryon is a Japanese regenerative-medicine venture developing platelet products derived from human iPS cells, including HLA-homozygous iPS-cell-derived platelets (MEG-002) that have advanced into clinical trials. It became a subsidiary of Sysmex Corporation in 2023.

1 investor

Mesenbio develops extracellular vesicle (EV) therapeutics derived from mesenchymal stem cells, using its FT-01 platform to enable scalable, GMP-ready EV manufacturing for regenerative medicine. The company is advancing a licensing-ready production platform and preclinical therapeutic candidate (MEV-N01) targeting rheumatoid arthritis.

1 investor

Mighty Therapeutics is a biopharmaceutical company developing mitochondria-targeted medicines to treat mitochondrial dysfunction in rare genetic mitochondrial diseases and common age-related conditions. Its pipeline spans rare genetic diseases, ophthalmic disorders, and neurological conditions, and it delivered the first approved therapy for Barth syndrome.

1 investor

Mimio makes a daily supplement built from fasting metabolites that aims to recreate the cellular health and longevity benefits of prolonged fasting without requiring users to fast. The consumer product is positioned around autophagy support, healthy aging, appetite control, and metabolic health.

1 investor

Miromatrix develops bioengineered human organs using a proprietary perfusion decellularization and recellularization technology, in which cells are removed from a pig organ and human cells are introduced into the resulting matrix. The company aims to create fully transplantable human organs to address the shortage of donor organs for transplant patients in the U.S.

1 investor

Mitrix Bio develops bioreactor-grown young mitochondria encased in extracellular vesicles ("Mitlets") intended for transplantation to supplement aging cells. The company targets mitochondrial dysfunction implicated in age-related diseases such as Alzheimer's, retinal disease, liver dysfunction, and immune senescence.

1 investor

Modern Age operates longevity-focused health clinics offering aging wellness assessments that include blood draws, bone scans, cognitive tests, and clinician consultations, plus treatments such as Botox, microneedling, hormone panels, and NAD+ IV therapy. It serves consumers seeking to proactively manage the health and cosmetic effects of aging.

1 investor

Momentum TX develops therapeutics targeting the aging process to treat age-related conditions of the central and peripheral nervous systems, with a focus on neurodegeneration. It uses in silico, in vitro, and in vivo methods and proteomics data to identify drug targets that restore protein configurations altered in the aged brain.

1 investor

Monarch operates wellness clubs offering an integrated membership that combines medical care with blood panels, strength and conditioning coaching, nutrition guidance, physical therapy, recovery services, and community. Its offerings share member data across medical teams and coaches to coordinate health, fitness, and longevity goals.

1 investor

MORROW builds a health community and physical space combining licensed longevity medical services with AI and technology-based protocols to help people improve their long-term health and habits. Based in Singapore, it focuses on closing the gap between lifespan and healthspan for aging adults.

1 investor

My Dementia Companion is a practical, evidence-based digital tool that guides carers, people living with dementia, and professionals on managing challenges at home and navigating the dementia care journey. Aimed at Australian families and health professionals, its carer tool can be funded through government programs such as HCP, Carer Gateway, or NDIS.

1 investor

Myospan develops smarter protein systems and science-based guidance focused on muscle longevity and healthy aging, targeting adults 35+ who want to maintain strength, recovery, and mobility. It offers a coaching program (the Muscle Longevity System), a podcast, and educational guides on nutrition, amino acids, and resistance training.

1 investor

Neotis develops immunotherapies to counteract age-related tissue decline by directing the immune system, with an initial focus on fibrotic disease. The company combines expertise in immunology, senescence, and biomarker development.

1 investor

NeuroAge offers multi-modal brain health testing that combines cognitive games, volumetric MRI, whole-genome sequencing, and blood biomarker tests to measure "brain age" and dementia risk for individuals concerned about neurodegenerative disease. It provides a unified dashboard, personalized recommendations, and brain training aimed at early detection of Alzheimer's and cognitive decline.

1 investor

Neuronity develops therapies that enhance immune cell activity in the aging brain to prevent neurodegenerative disease progression. The company targets patients with age-related neurological conditions.

1 investor

NOHO is a concierge wellness membership service that designs personalized peptide protocols based on a member's biology, health history, and goals, with support from clinicians and a dedicated concierge team. It sources peptides from FDA-inspected facilities and focuses on health optimization, performance, recovery, and vitality.

1 investor

nuAura offers advanced blood testing covering 100+ biomarkers, doctor consultations, and daily personalised guidance, distilling results into a single health score and actionable advice on nutrition, movement, and mental well-being. It serves individuals seeking to interpret their health data across metabolic, hormonal, nutritional, and inflammatory signals.

1 investor

Nuchido develops Nuchido TIME+, an NAD+ boosting dietary supplement aimed at supporting cellular repair and healthy aging in consumers. The company focuses on science-backed longevity and wellness products for people seeking to counter age-related declines in energy, cognition, and skin health.

1 investor

Nula Therapeutics develops targeted small-molecule medicines that correct how the nuclear envelope regulates gene expression and cellular function. The company focuses on treating age-related diseases including metabolic dysfunction, neurodegeneration, and cancer, and on extending healthspan.

1 investor

Oak Street Health operates a network of primary care centers focused on preventive and comprehensive care for older adults, offering personalized wellness plans, integrated health services, and care coordination with specialists. Founded in 2012, it is now part of CVS Health.

1 investor

Okava develops medicines for dogs and cats by adapting established human pharmaceuticals for veterinary use, targeting conditions such as obesity, diabetes, arthritis, and chronic inflammation. The company operates in the animal health and pet pharmaceutical sector.

1 investor

OmniActive develops science-backed nutritional ingredient solutions and delivery technologies for brand partners in the consumer wellness, performance, and healthspan markets. It operates an in-house R&D center and supports its ingredients with clinical studies, selling to manufacturers and consumer supplement brands worldwide.

1 investor

Omniscope develops diagnostics and therapeutics technology based on the convergence of AI and immunology, aiming to interpret immune system data to generate therapeutics, develop diagnostics, and monitor patients. Founded in 2020, the company applies machine learning to immunology with a focus on health equity.

1 investor